Home About us Science Literature IR Links Contact

 

 

 

 

Novel anti-metastatic treatments

Cancer affects one in three individuals and is the leading cause of death below the age of 75 in most Western countries. Enormous efforts have been focused on improving diagnostics and therapeutics for cancer. However, the overall mortality rates remain virtually constant.

The primary tumour is rarely the cause of death of cancer patients. In fact, in the vast majority of cases, cancer-associated mortality is the result of cancer cell dissemination to other organs, i.e. metastasis. The inherent problem with most current therapeutic approaches is their failure to target the dissemination process.

Present share price
(20 min delay)

+ / - 0.10
% 0.67
Last 15.10
High 15.50
Low 14.90

celler

 Wnt-5a negative and positive tumour cells

WntResarch at a glance

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007.

The focus and aim of WntResearch is to develop novel anti-metastatic therapies for the treatment of cancer patients and thereby meet a large medical need.

The company has two projects Foxy-5 and Box-5. The lead project is Foxy-5 which is in phase 1. 

WntResearch to receive patent for Foxy-5 in Canada 2014-04-10 Swedish English

New issue starts today

2014-04-10 Swedish only

Previous news


MEDIA COVERAGE

 

 

 

 

 

WntResearch AB · Södra Promenaden 69 · SE-211 38 Malmö · Sweden · www.wntresearch.com

 · Last modified 2014-04-10

 

Visitors since 1st of October 2009

Website counter

 

 

Designed by Xpresso Publishing